Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

June 9, 2017September 20, 2017

Keytruda Helped Patients with Metastatic Triple-Negative Breast Cancer, Studies Find

News

Keytruda (pembrolizumab) was effective in treating triple-negative breast cancer regardless of whether women had received previous treatment, according to data presented at the 2017 American Society of Clinical Oncology (ASCO) Annual ... Read more

May 26, 2017May 26, 2017

Even One Alcoholic Drink a Day Enough to Raise Breast Cancer Risk, New Report Warns

News

Just one alcohol-containing beverage a day — less than a standard drink — is sufficient to increase a woman’s risk of breast cancer, according to a new report by the ... Read more

May 22, 2017May 22, 2017

More Women Living With Metastatic Breast Cancer Than Ever, Thanks to Better Treatments, Study Finds

News

The number of women living with metastatic breast cancer (MBC) is increasing. But that’s not necessarily a bad thing, say researchers, noting that today’s better treatments allow patients to live ... Read more

April 25, 2017

AbbVie’s Veliparib and Chemotherapy Combo Trial Failed in Early Triple Negative Breast Cancer

News

AbbVie’s investigational oral PARP inhibitor veliparib was not effective against early-stage triple-negative breast cancer when given in combination with chemotherapy, the company recently announced. Despite the drawback, AbbVie researchers believe ... Read more

April 4, 2017April 4, 2017

Despite Database Discrepancies, Black Women Still Far Less Likely to Get Immediate Breast Reconstruction

News

Three national databases report highly varying rates of immediate breast reconstruction (IBR) among minority breast cancer patients undergoing breast removal for breast cancer, bringing focus to the already important issue of lower ... Read more

March 24, 2017March 24, 2017

New Allegations Surface in Controversy Over Breast Cancer Risk from Hormone Replacement Therapy

News

News stories about a clinical trial in 2002 prompted many postmenopausal women to avoid hormone replacement therapy out of fear they would develop breast cancer. The study also touched off ... Read more

March 3, 2017March 3, 2017

Ibrance Offers No More Benefits Than Other Breast Cancer Treatments, Analysis Says

News

The breast cancer therapy Ibrance (palbociclib) offers no more benefits than treatments with which it was compared in clinical trials, according to an analysis by the German Institute for Quality and Efficiency ... Read more

February 17, 2017

Cells Near Breast Cancer Play Role in Its Spread, Could Be Therapy Avenue, Study Reports

News

The environment that surrounds breast cancer cells is crucial to the cells migrating to other parts of the body and taking root, according to a study arguing that new treatments could ... Read more

January 13, 2017

Enzymes’ Role in Development, Treatment of Estrogen Receptor-positive Cancer Identified

News

Researchers have identified two new factors that may help to determine whether a patient with estrogen receptor-positive breast cancer will respond to treatment. In addition to preventing the estrogen receptor from ... Read more

December 19, 2016December 20, 2016

Veliparib Improved Response to Chemotherapy Without Boosting Survival

News

Adding the experimental PARP inhibitor veliparib to chemotherapy increased the number of patients who responded to treatment without worsening side effects, but failed to lengthen progression-free survival times, a breast ... Read more